Cargando…
Applications of the European Parkinson’s Disease Association sponsored Parkinson’s Disease Composite Scale (PDCS)
This study was addressed to determine the presence of Parkinson disease (PD) manifestations, their distribution according to motor subtypes, and the relationships with health-related quality of life (QoL) using the recently validated European Parkinson’s Disease Association sponsored Parkinson’s Dis...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6881347/ https://www.ncbi.nlm.nih.gov/pubmed/31798050 http://dx.doi.org/10.1038/s41531-019-0097-1 |
_version_ | 1783473927504265216 |
---|---|
author | Balestrino, Roberta Hurtado-Gonzalez, Carlos Alberto Stocchi, Fabrizio Radicati, Fabiana Giada Chaudhuri, K. Ray Rodriguez-Blazquez, Carmen Martinez-Martin, Pablo |
author_facet | Balestrino, Roberta Hurtado-Gonzalez, Carlos Alberto Stocchi, Fabrizio Radicati, Fabiana Giada Chaudhuri, K. Ray Rodriguez-Blazquez, Carmen Martinez-Martin, Pablo |
author_sort | Balestrino, Roberta |
collection | PubMed |
description | This study was addressed to determine the presence of Parkinson disease (PD) manifestations, their distribution according to motor subtypes, and the relationships with health-related quality of life (QoL) using the recently validated European Parkinson’s Disease Association sponsored Parkinson’s Disease Composite Scale (PDCS). Frequency of symptoms was determined by the scores of items (present if >0). Using ROC analysis and Youden method, MDS-UPDRS motor subtypes were projected on the PDCS to achieve a comparable classification based on the PDCS scores. The same method was used to estimate severity levels from other measures in the study. The association between the PDCS and QoL (PDQ-39) was analyzed by correlation and multiple linear regression. The sample consisted of 776 PD patients. We found that the frequency of PD manifestations with PDCS and MDS-UPDRS were overlapping, the average difference between scales being 5.5% only. Using the MDS-UPDRS subtyping, 215 patients (27.7%) were assigned as Tremor Dominant (TD), 60 (7.7%) Indeterminate, and 501 (64.6%) Postural Instability and Gait Difficulty (PIGD) in this cohort. With this classification as criterion, the analogous PDCS-based ratio provided these cut-off values: TD subtype, ≥1.06; Indeterminate, <1.06 but >0.65; and PIGD, <0.65. The agreement between the two scales on this classification was substantial (87.6%; kappa = 0.69). PDCS total score cut-offs for PD severity were: 23/24 for mild/moderate and 41/42 for moderate/severe. Moderate to high correlations (r = 0.35–0.80) between PDCS and PDQ-39 were obtained, and the four PDCS domains showed a significant independent influence on QoL. The conclusions are: (1) the PDCS assessed the frequency of PD symptoms analogous to the MDS-UPDRS; (2) motor subtypes and severity levels can be determined with the PDCS; (3) a significant association between PDCS and QoL scores exists. |
format | Online Article Text |
id | pubmed-6881347 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-68813472019-12-03 Applications of the European Parkinson’s Disease Association sponsored Parkinson’s Disease Composite Scale (PDCS) Balestrino, Roberta Hurtado-Gonzalez, Carlos Alberto Stocchi, Fabrizio Radicati, Fabiana Giada Chaudhuri, K. Ray Rodriguez-Blazquez, Carmen Martinez-Martin, Pablo NPJ Parkinsons Dis Article This study was addressed to determine the presence of Parkinson disease (PD) manifestations, their distribution according to motor subtypes, and the relationships with health-related quality of life (QoL) using the recently validated European Parkinson’s Disease Association sponsored Parkinson’s Disease Composite Scale (PDCS). Frequency of symptoms was determined by the scores of items (present if >0). Using ROC analysis and Youden method, MDS-UPDRS motor subtypes were projected on the PDCS to achieve a comparable classification based on the PDCS scores. The same method was used to estimate severity levels from other measures in the study. The association between the PDCS and QoL (PDQ-39) was analyzed by correlation and multiple linear regression. The sample consisted of 776 PD patients. We found that the frequency of PD manifestations with PDCS and MDS-UPDRS were overlapping, the average difference between scales being 5.5% only. Using the MDS-UPDRS subtyping, 215 patients (27.7%) were assigned as Tremor Dominant (TD), 60 (7.7%) Indeterminate, and 501 (64.6%) Postural Instability and Gait Difficulty (PIGD) in this cohort. With this classification as criterion, the analogous PDCS-based ratio provided these cut-off values: TD subtype, ≥1.06; Indeterminate, <1.06 but >0.65; and PIGD, <0.65. The agreement between the two scales on this classification was substantial (87.6%; kappa = 0.69). PDCS total score cut-offs for PD severity were: 23/24 for mild/moderate and 41/42 for moderate/severe. Moderate to high correlations (r = 0.35–0.80) between PDCS and PDQ-39 were obtained, and the four PDCS domains showed a significant independent influence on QoL. The conclusions are: (1) the PDCS assessed the frequency of PD symptoms analogous to the MDS-UPDRS; (2) motor subtypes and severity levels can be determined with the PDCS; (3) a significant association between PDCS and QoL scores exists. Nature Publishing Group UK 2019-11-27 /pmc/articles/PMC6881347/ /pubmed/31798050 http://dx.doi.org/10.1038/s41531-019-0097-1 Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Balestrino, Roberta Hurtado-Gonzalez, Carlos Alberto Stocchi, Fabrizio Radicati, Fabiana Giada Chaudhuri, K. Ray Rodriguez-Blazquez, Carmen Martinez-Martin, Pablo Applications of the European Parkinson’s Disease Association sponsored Parkinson’s Disease Composite Scale (PDCS) |
title | Applications of the European Parkinson’s Disease Association sponsored Parkinson’s Disease Composite Scale (PDCS) |
title_full | Applications of the European Parkinson’s Disease Association sponsored Parkinson’s Disease Composite Scale (PDCS) |
title_fullStr | Applications of the European Parkinson’s Disease Association sponsored Parkinson’s Disease Composite Scale (PDCS) |
title_full_unstemmed | Applications of the European Parkinson’s Disease Association sponsored Parkinson’s Disease Composite Scale (PDCS) |
title_short | Applications of the European Parkinson’s Disease Association sponsored Parkinson’s Disease Composite Scale (PDCS) |
title_sort | applications of the european parkinson’s disease association sponsored parkinson’s disease composite scale (pdcs) |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6881347/ https://www.ncbi.nlm.nih.gov/pubmed/31798050 http://dx.doi.org/10.1038/s41531-019-0097-1 |
work_keys_str_mv | AT balestrinoroberta applicationsoftheeuropeanparkinsonsdiseaseassociationsponsoredparkinsonsdiseasecompositescalepdcs AT hurtadogonzalezcarlosalberto applicationsoftheeuropeanparkinsonsdiseaseassociationsponsoredparkinsonsdiseasecompositescalepdcs AT stocchifabrizio applicationsoftheeuropeanparkinsonsdiseaseassociationsponsoredparkinsonsdiseasecompositescalepdcs AT radicatifabianagiada applicationsoftheeuropeanparkinsonsdiseaseassociationsponsoredparkinsonsdiseasecompositescalepdcs AT chaudhurikray applicationsoftheeuropeanparkinsonsdiseaseassociationsponsoredparkinsonsdiseasecompositescalepdcs AT rodriguezblazquezcarmen applicationsoftheeuropeanparkinsonsdiseaseassociationsponsoredparkinsonsdiseasecompositescalepdcs AT martinezmartinpablo applicationsoftheeuropeanparkinsonsdiseaseassociationsponsoredparkinsonsdiseasecompositescalepdcs AT applicationsoftheeuropeanparkinsonsdiseaseassociationsponsoredparkinsonsdiseasecompositescalepdcs |